J. G. Boretto,E. Zaidenberg,G. L. Gallucci,V. Alfie and P. De Carli. Delayed Repair of Ulnar Artery at the Distal Forearm. Hand (N Y). 2017;12(2):10.1177/1558944716643275.
Delayed Repair of Ulnar Artery at the Distal Forearm Ver más »
A. Pichon-Riviere,S. Garcia-Marti,W. Oortwijn,F. Augustovski and L. Sampietro-Colom. Defining the value of health technologies in Latin America: Development in value frameworks to inform the prioritization of health care resources. International Journal of Technology Assessment in Health Care. 2019;35(1):10.1017/s0266462319000126.
A. Pichon-Riviere,S. Garcia-Marti,W. Oortwijn,F. Augustovski and L. Sampietro-Colom. Definiendo el valor de las tecnologías sanitarias en Latino-América: desarrollo de marcos de valor para informar la priorización de recursos sanitarios. Int J Technol Assess Health Care. 2019;35(1):10.1017/s0266462319000126.
A. Pichon-Riviere,J. Caporale,C. von Schulz-Hausmann and F. A. Augustovski. COSTS OF INSULIN GLARGINE AND INSULIN DETEMIR IN INTENSIVE INSULIN THERAPY FOR TYPE 1 DIABETES MELLITUS IN ARGENTINA: A PROBABILISTIC MODEL. Value in Health. 2009;12(7):10.1016/s1098-3015(10)75391-2.
A. Alcaraz,J. Gonzalez-Zuelgaray and F. Augustovski. Cost-Effectivity of Implantable Cardioverter Defibrillators in Patients with Risk Factors for Sudden Death in Argentina. Value in Health. 2011;14(5):10.1016/j.jval.2011.05.030.
S. G. Marti,A. Alcaraz,P. Valanzasca,O. U. Garay,M. McMullen,L. R. Ares,C. A. Obando and J. Caporale. COST-EFFECTIVENESS OF TELAPREVIR IN GENOTYPE 1 CHRONIC HEPATITIS-C VIRUS INFECTION IN VENEZUELA. Value in Health. 2013;16(7).
S. G. Marti,A. Alcaraz,P. Valanzasca,U. G. Ulises,M. McMullen,L. R. Ares,I. Peirano,D. O. Reisberg,A. S. Ried,J. Poniachik,J. R. B. Barril and J. Caporale. COST-EFFECTIVENESS OF TELAPREVIR IN GENOTYPE 1 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN CHILE. Value in Health. 2013;16(7).
S. G. Marti,A. Alcaraz,P. Valanzasca,O. U. Garay,M. McMullen,L. R. Ares,V. Idrovo,J. P. Ortiz,M. Tapias,J. Obregon,J. G. Ariza and J. Caporale. COST-EFFECTIVENESS OF TELAPREVIR IN GENOTYPE 1 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN COLOMBIA. Value in Health. 2013;16(7).
S. G. Marti,A. Alcaraz,P. Valanzasca,U. G. Ulises,M. McMullen,L. R. Ares,I. Peirano,F. Bessone,H. Fainboim,A. Gadano,O. Galdame,C. Vujacich and J. Caporale. COST-EFFECTIVENESS OF TELAPREVIR IN GENOTYPE 1 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN ARGENTINA. Value in Health. 2013;16(7).
R. Augustovski,A. Palacios,A. Beratarrechea,F. Diez-Canseco,V. Irazola,M. Ramirez-Zea,A. Pichon-Riyiere and A. Rubinstein. COST-EFFECTIVENESS ANALYSIS OF A RANDOMIZED TRIAL OF AN MHEALTH INTERVENTION TO IMPROVE CARDIOMETABOLIC PROFILE IN PREHYPERTENSIVE SUBJECTS FROM LOW-RESOURCE URBAN SETTINGS IN LATIN AMERICA. Value in Health. 2017;20(9).
